| Registry | NCT02357654 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 4 |
| Study type | Interventional; randomized, parallel, masking: quadruple, treatment |
| Enrollment | 350 (Estimated) |
| Sponsor | University Reproductive Associates (Other) |
| Conditions | Infertility |
| Interventions | GnRH, placebo (Drug) |
| Dates | start 2015-11-01, primary completion 2027-07-01 (estimated), completion 2027-11-01 (estimated), first posted 2015-02-06, last updated 2026-10-19 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Infertility All trials of GnRH All trials of placebo
During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .
see above
| Arm | Type | Interventions | Description |
|---|---|---|---|
| GnRH agonist | Experimental | Drug: GnRH | |
| Placebo | Placebo comparator | Drug: placebo |
Sex: Female, ages: 18 Years to 40 Years
Inclusion Criteria: * women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old. Exclusion Criteria: * day 3 transfers
| Facility | City | Country | Status |
|---|---|---|---|
| University Reproductive Associates | Hasbrouck Heights, New Jersey | United States |